MDR1 reversal: Criteria for clinical trials designed to overcome the multidrug resistance phenotype

Leukemia

Volumn 10, Issue SUPPL. 3, 1996, Pages

  Hegewisch Becker, S ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acute leukemia; Chemosensitizer; Idarubicin; MDR modulator; Multidrug resistance; P glycoprotein

Indexed keywords

ANTIESTROGEN; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DEXNIGULDIPINE; DIPYRIDAMOLE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; IDARUBICINOL; MITOXANTRONE; QUININE; STEROID; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; VALSPODAR; VERAPAMIL; VINCRISTINE;

ACUTE LEUKEMIA; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG HALF LIFE; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; MULTIDRUG RESISTANCE; NEPHROTOXICITY; PRIORITY JOURNAL; THROMBOSIS; TINNITUS; VERTIGO;

EID: 0029846036     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Roessner A, Ueda Y, Bockhorn-Dworniczak B, Blasius S, Peters A, Wuisman P, Ritter J, Paulussen M, Jurgens H, Bocker W. Prognostic implication of immunodetection of p-glycoprotein in Ewing's sarcoma. J Cancer Res Clin Oncol 1993; 119: 185-190.
2. Chan HSL, Thorner PS, Haddad C, Ling V. Immunohistochemical detection of p-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990; 8: 689-704.
3. Holzmayer TA, Hilsenbeck S, von Hoff DD, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992; 84: 1486-1492.
4. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R, Chassagne J. Clinical relevance of immunohistochemical detection of multidrug resistance in p-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991; 83: 111-116.
5. Wunder JS, Bell RS, Wold L, Andrulis IL. Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J Orthop Res 1993; 11: 396-403.
6. Fisher CA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995; 9: 363-382.
7. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistance phenotype. Blood 1992; 80: 2729-2734.
8. Arceci RJ, Croop JM, Horwitz SB, Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium. Proc Natl Acad Sci USA 1988; 85: 4350-4354.
9. Hegewisch-Becker S, Szudra A, Hossfeld DK. Exposure to lipophilic industrial solvents leads to increased P-glycoprotein expression in peripheral blood cells. Br J Haematol 1993; 85: 220-222.
10. Jancis EM, Chen HX, Carbone R, Hochberg RB, Dannies PS. Rapid stimulation of rhodamine 123 efflux from multidrug resistant KB cells by progesterone. Biochem Pharmacol 1993; 46: 1613-1619.
11. Gosland MP, Brophy NA, Duran GE, Yahanda AM, Adlaer KM, Hardy RI, Halsey J, Sikic BI. Bilirubin: a physiological substrate for the multidrug transporter. Proc Am Assoc Cancer Res 1991; 32: 426a.
12. Van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J, Giaccone C. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 1993; 67: 284-289.
13. Burt RK, Thorgeirsson SS. Coinduction of mdr1 multidrug resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst 1988; 80: 1383-1386.
14. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance p-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-476.
15. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P. Mdr1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708-712.
16. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI. Clinical trials of modulation of multidrug resistance. Cancer 1993; 72: 3502-3514.
17. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parillo JE, Young RC. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987; 5: 641-647.
18. Mross K, Mayer U, Wörmann B, Hanauske AR, Lehmann M, Hossfeld DK. Pharmacokinetics and toxicity of dexniguldipine after single and repetitive daily 4 h infusions in cancer patients. Anti-Cancer Drugs 1994; 5: 45.
19. Millward MJ, Cantwell BM, Lien EA, Carmichael J, Harris AL. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 1992; 28: 805-810.
20. Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M, Guy H. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 1992; 10: 1730-1736.
21. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI. Alteration of etoposide pharmacokinetics and pharmcodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-1642.
22. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-1660.
23. Bartlett N, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994; 12: 835-842.
24. Solary E, Quiquandon I, Moreau P, Witz B, Casanovas RO, Genne P, Cahm JY, Sadoun A, Pignon B, Berthou C, Maloisel F, Guyotat D, Casassus P, Gardembas M, Lamy Y, Audhuy B, Colombat P, Harousseau JL. Phase III multicentric randomized study of quinine as a potential MDR reversing agent in acute leukemias. Anti-Cancer Drugs 1994; 5: 46.
25. Harker WG, Slade DL, Dalton WS. Multidrug resistance in mitoxantrone selected HL-60 cells in the absence of P-glycoprotein overexpression. Cancer Res 1989; 49: 4542-4549.
26. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PLC. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a southeastern cancer study group study. J Clin Oncol 1992; 10: 1103-1111.
27. Wiernik PH, Banks PLC, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313-319.
28. Wiernik PH. Idarubicin in induction therapy in AML. Ann Hematol 1995; 70 (Suppl 2): 99.
29. Reiffers J, Rigal-Huguet F, Stoppa AM, Michallet M, Marit G, Attal M, Gastaut JA, Corront B, Lepeu G, Routy M, Cony-Makhoul P, Pris J, Hollard D, Maraninchi D, Mercier M, Hurteluop P. Prospective study comparing idarubicn and daunorubicin in elderly patients with acute myeloid leukemia. Haematol Blood Transfus 1992; 34: 628-631.
30. Estey EH, Kantarjian H, Keating M. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. Sem Oncol 1993; 20: 1-5.
31. Gieseler F, Pfeifer W, Briden Th, Clark M, Wilms K. Idarubicin: intracellular mechanisms of action. Ann Hematol 1995; 70 (Suppl 2): 99.
32. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267-3273.
33. Robert J. Pharmacological properties of oral idarubicin. Clin Drug Invest 1995; 9: 1-8.
34. Jonsson B, Nilsson K, Nygren P, Larsson R. SDZ PSC 833, a novel potent in vitro chemosensitizer in multiple myeloma. Anti-Cancer Drug 1992; 3: 641-646.
35. Sato H, Preisler R, Day R, Raza A, Larson R, Browman G, Goldberg J, Vogler R, Grundwald H, Gottlieb A, Bennett J, Gottesman M, Pastan I. Mdr1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol 1990; 75: 340-345.
36. Kuwazuru Y, Yoshimura A, Hanada S, Utsunomiya A, Makino T, Ishibashi K, Kodoma M, Iwahashi M, Arima T, Akiyama SI. Expression of the multidrug transporter, p-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 1990; 66: 868-873.
37. Marie JP, Legrand O, Russo D, Zhou D, Suberville AM, Zittoun R. Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis. Leuk Lymphoma 1992; 8: 261-265.
38. Michieli M, Damiani D, Geromon A, Michelutti A, Fanin R, Raspadori D, Russo D, Visani G, Dinota A, Pileri S. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocyric leukemia. Eur J Haematol 1992; 48: 87-92.
39. Campos L, Guyotat D, Jaffar C, Solary E, Archimbaud E, Treille D. Correlation of mdr1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. Eur J Haematol 1992; 48: 254-258.
40. Gruber A, Vitols S, Norgren S, Areström I, Peterson C, Björkholm M, Reizenstein P, Luthman H. Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia. Br J Cancer 1992; 66: 266-272.
41. + acute myeloid leukemia cells. Blood 1993; 82: 3157-3162.
42. Hegewisch-Becker S, Fliegner M, Tsuruo T, Zeller W, Hossfeld DK. Multidrug resistance (mdr1) in adult acute leukemia at diagnosis: correlation with response to induction chemotherapy. Onkologie 1993; 16: 264-269.
43. Stasi R, del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T, Cox C, Dallapiccola B, Papa G. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood 1994; 83: 1619-1625.
44. Ball ED, Lawrence D, Malnar M, Ciminelli N, Mayer R, Wurster-Hill D, Davey FR, Bloomfield CD. Correlation of CD34 and multidrug resistance P170 with FAB and cytogenetics but not prognosis in acute myeloid leukemia (AML). Blood 1990; 76: 252a.
45. + patients more frequently achieve CR with high dose cytosine arabinoside. Proc Am Soc Clin Oncol 1992; 11: 262.
46. Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperon J, Fauchet R. Expression of the multidrug resistance-associated p-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394-2398.
47. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1990; 78: 44-50.
48. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-424.
49. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9: 17-24.
50. Sonneveld P, Durie BGM, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Löwenberg B, Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992; 340: 255-259.
51. Sonneveld P, Schoester M, de Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol 1994; 12: 1584-1591.
52. Sonneveld P, Marie JP, Lokhorst HM, Nooter K, Schoester M. Clinical modulation of multidrug resistance in VAD-refractory multiple myeloma: studies with cyclosporin and SDZ PSC 833. Anti-Cancer Drugs 1994; 5 (Suppl 1): 72.
53. Scheulen ME, Meusers P, Schröder J. Effect of dexniguldipine (B935) on the efficacy of daunorubicin (DNR) plus high dose cytosine-arabinosine (ara-C in refractory acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 1993; 12: 308.